(Q50473987)

English

A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment.

scientific article published on 21 November 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/17118709

A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/17118709

author name string

Andrea Heger

1

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/17118709

Jürgen Römisch

2

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/17118709

Tor-Einar Svae

3

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/17118709

publication date

21 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/17118709

Transfusion and Apheresis Science

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/17118709

35

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/17118709

3

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/17118709

223-233

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/17118709

Viral inactivation of fresh frozen plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Risks and side effects of therapy with plasma and plasma fractions

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Pathogen inactivation techniques

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Inactivation of viruses in fresh-frozen plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Solvent/detergent treatment of human plasma--a very robust method for virus inactivation. Validated virus safety of OCTAPLAS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Viral safety of solvent/detergent-treated plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Universal solvent/detergent-treated fresh frozen plasma (Uniplas--rationale and clinical properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Proteomics of methylene blue photo-treated plasma before and after removal of the dye by an absorbent filter

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Manufacture and in vitro characterization of a solvent/detergent-treated human plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Solvent/detergent-treated plasma: composition, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48 h after thawing

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Coagulation factor content of cryoprecipitate prepared from methylene blue plus light virus-inactivated plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

What's happening? The quality of methylene blue treated FFP and cryo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Measurement of von Willebrand factor activity: relative effects of ABO blood type and race

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

The relationship between ABO histo-blood group, factor VIII and von Willebrand factor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Population-based distributions of haemostatic variables

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Distinctive role of histidine-16 of the B beta chain of fibrinogen in the end-to-end association of fibrin

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Photo-oxidation of histidine as a probe for aminoterminal conformational changes during fibrinogen-fibrin conversion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Methylene-blue-photoinactivated plasma and its contribution to blood safety

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

Issues in the development of medical products based on human plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSCI.2006.08.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.TRANSCI.2006.08.008

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/17118709

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 March 2018

http://europepmc.org/abstract/MED/17118709

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50473987&oldid=1381901601"